Immuron - Crunchbase Company Profile & Funding

Q: Where is Immuron's headquarters?

Immuron is located in Carlton, Victoria, Australia.

Q: Who invested in Immuron?

Immuron has 3 investors including U.S. Department of Defense And Walter Reed Army Institute of Research.

Q: When was the last funding round for Immuron?

Immuron closed its last funding round on obfuscated from a Post-IPO Equity round.

Overview

Immuron

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Immuron

CB Rank

150965

Immuron focuses on oral immunotherapy using polyclonal antibody products for humans.

Founded

obfuscation

Public

Post-IPO Equity

Carlton, Victoria, Australia

1-10

www.immuron.com/

Biopharma

Biotechnology

Manufacturing

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Grant

OBF

obfuscation

Grant

OBF

obfuscation

Key People

Steven Lydeamore: CEO
Phillip Hains: Company Secretary & CFO

Details

Legal Name

Immuron Limited

Operating Status

Active

Stock Symbol

ASX:IMC

Company Type

For Profit

About the Company

Immuron Ltd is a publicly listed Australian bio pharmaceutical Microbiome company focused on oral immunotherapy using polyclonal antibody products for humans. Immuron is a uniquely positioned company developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis.

Phone Number

+610398245254

Contact Email

info@immuron.com

Predictions & Insights

Growth Insight

See this Growth Insight

Immuron is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Products & Services

Travelan

An over-the-counter supplement designed to reduce the risk of travelers' diarrhea and support digestive health by targeting and neutralizing pathogenic bacteria in the gastrointestinal tract.

Protectyn

A formulation containing hyperimmune bovine colostrum enriched with anti-LPS antibodies, aimed at removing harmful bacteria and LPS toxins from the gut to restore balance and support liver health.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Immuron	—	obfuscated obfuscation	—	Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
U.S. Department of Defense	Yes	Grant - Immuron	—
U.S. Department of Defense	Yes	Grant - Immuron	—
U.S. Department of Defense	Yes	Grant - Immuron	—
U.S. Department of Defense	Yes	Grant - Immuron	—
U.S. Department of Defense	Yes	Grant - Immuron	—

Investments

Investment Breakdown

Number of Investments

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation

Investment Breakdown

Number of Investments

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation
obfuscated obfuscation	Ateria Health	Yes	Corporate Round - Ateria Health	obfuscated obfuscation